Rōvn Comparable Companies & Valuation Football Field

Date: regenerated 2026-07-22 against Rōvn master canon generation 8 (effective 2026-07-21). Originally drafted 2026-05-14; rebuilt 2026-05-28 with a corrected model and verified funding sourcing. Purpose: Public-comp benchmarking to frame a future Series A valuation expectation for Rōvn.

Sourcing standard. An earlier version of this page carried blanket "(est), Crunchbase/Pitchbook" labels and two incorrect transaction claims (Verifiable "acquired by Stripe"; Modio "acquired by HealthStream, $168M / $15M ARR"). Both were corrected on 2026-05-28 with the primary-source citations retained below, each with its own date. Where a private valuation is not reliably disclosed, it is marked (undisclosed) rather than guessed. Sources: company press releases, TechCrunch, PR Newswire, and PitchBook/CB Insights/Tracxn abstracts, checked May 2026; each figure keeps its own transaction date. All Y-case Rōvn ARR figures are projections, matching 3_CASE_MODEL_SUMMARY.md (Bear $30M / Base $45M / Bull $60M). Rōvn is pre-launchStage03.1 Company Overview · pre-launch by design; zero signed pilots and zero paying customers per canon generation 8, Section 42 by design: zero revenue, zero signed pilots, zero paying customers as of July 2026. Nothing on this page is Rōvn traction proof.

1. Comp Universe (verified funding rounds)

Rōvn intersects three comp categories: healthcare credentialing and provider-data platforms, identity verification platforms, and healthcare staffing marketplaces. Every figure below carries its own transaction date; undisclosed valuations stay undisclosed.

Notes on the corrections vs. the prior draft: - Verifiable is independent, not a Stripe acquisition. Closest API-credentialing comp; $27M Series B (2023). Any "Stripe acquired Verifiable" claim elsewhere in the package is wrong and should be struck. - Modio was acquired by CHG Healthcare in 2019 for undisclosed terms, there is no public "$168M / $15M ARR / HealthStream / 2022" transaction. The earlier 11.2x "precedent" built on that figure is removed; do not use it as an exit-multiple anchor. - Medallion, CertifyOS/Certify, and Andros do not publicly disclose valuations; revenue/multiples shown only where a primary source exists (Medallion ~$50.6M 2024 rev per Latka).

2. Multiple Distribution by Category

Multiples for the credentialing-platform band are inferred from disclosed total funding, revenue where reported (e.g. Medallion ~$50.6M 2024 rev against $130M cumulative raised), and stage, not from disclosed post-money valuations, most of which are undisclosed. Treat the 8-12x band as a stage-and-category inference, not a quoted transaction multiple.

Rōvn position: Healthcare credentialing / provider-data platform economics, with network reuse dynamics that argue toward the identity-category band and governed READ API access as an additional surface. Defensible at 8-12x at a future Series A. Bear: 6x. Bull: 10-12x if the measured network economics (a materially cheaper second Work Activation) hold.

3. Football Field Chart (Concept): corrected model

Rōvn's Series A valuation range across methods, all reconciled to the corrected 3-case model (Bear $30M / Base $45M / Bull $60M Y5; Y2 Base ARR ~$2.4M).

Valuation Method                         | $0M   $25M  $50M  $75M  $100M $125M $150M $175M
-----------------------------------------|------|-----|-----|-----|-----|-----|-----|-----
1. Public-comp ARR multiple (8-14x)      |      [===##===]
   Y2 ARR ~$2.4M × 8-14x = $19-34M (early Series A)

2. Public-comp ARR multiple (8-12x)      |              [======##======]
   Y3 ARR ~$9.9M × 8-12x = $79-119M (late Series A, Base)

3. Credentialing-band multiple (8-12x)   |      [===##===]
   Y2 ARR ~$2.4M × ~10x = ~$24M

4. DCF (30% discount, 6-10x exit)        |     [=====##=====]
   PV today: Bear $48.5M / Base $97.0M / Bull $161.6M (projection)

5. VC method (target ~6x return)         |   [==##==]
   Series A post-money target $30-50M

LEGEND: # = midpoint of range

(Concept view. All ranges derive from the projection cases above; none is a quoted offer or a measured result.)

4. Series A Valuation Recommendation

Recommended Series A target: $30-50M post-money at the ~18-month mark, presuming Base or better trajectory. This is a modeling target, not an offer.

Current round context (July 2026): the YC Fall 2026 application was submitted on 2026-07-10 and is under review. The canon financing sequence models a post-Demo-Day seed of roughly $5 million, sized against actual proof, burn, and the 18-to-24-month NCQA-CVO certification path. If YC declines, the company raises an independent lean pre-seed against the same milestones. Amount, valuation, exemption, and final terms remain CEO, board, and counsel decisions; terms are shared only once counsel confirms the offering exemption. Y5 ARR cases are projections, not actuals.

5. Discount/Premium Drivers vs. Comps

Premium drivers (push Rōvn toward the identity-category band, Persona/Plaid): - Agent-operated workflow with receipt-grade proof: AI compresses the work, source systems prove the facts, humans make every regulated decision. - Multi-surface revenue design: Readiness and Operator subscriptions priced on monitored lives, governed READ API access, implementation packages. Workers stay free forever. - Prospective network density: consented evidence reuse is designed to make the second Work Activation materially cheaper than the first. This is a falsifiable test, not a measured result. - Source-authority adapter pattern plus the NCQA-CVO delegation path (an 18-to-24-month clock started in Phase 0) as durable, legally reusable verification rights. - designed for HIPAA-governed workflowsHIPAA posture06.2 HIPAA Posture Memo · canonical procurement-safe phrasing (not 'compliant' / not 'certified') · BAA path subject to counsel and executionBAA posture06.4 Vendor BAA Matrix · customer BAA template at 08.9; SOC 2 path in progress = enterprise procurement readiness.

Discount drivers (push toward the staffing-marketplace band, Incredible Health/Vivian): - Pre-revenue (pre-launch by design, zero ARR as of July 2026, at the modeled seed stageRound stage02.1 Use of Funds · post-Demo-Day seed modeled at roughly $5M; terms silent until counsel confirms the exemption). - Healthcare adoption cycle is slow (long sales cycles). - Vertical concentration risk (no diversification outside healthcare). - First-time-CEO scaling risk.

Net position: Mid-band, 8-12x at a future Series A, with upside toward the identity-category band if the measured reuse economics hold.

6. Strategic Acquirers (For Series B+ Optionality)

Strategic-acquirer optionality is real: CHG (Modio 2019), HealthStream (active credentialing acquirer), and symplr (serial roll-up) have all transacted in or adjacent to this category in the last several years. Stripe is listed as a strategic-fit rationale only, there is no Stripe/Verifiable transaction.

7. Caveats

• 2026 multiples reflect a partial recovery from the 2022-2023 SaaS compression and a sharp re-rate in identity infra (Plaid fell from $13.4B in 2021 to $6.1B in 2025 before recovering to $8B in 2026). Multiples could drift either direction.
• Healthcare-specific multiples typically carry a discount to generic SaaS due to slow adoption and regulatory drag; Rōvn's AI/network positioning argues partly against it but does not erase it.
• Most credentialing-comp valuations are undisclosed; the 8-12x band is a stage-and-category inference, not a set of quoted transaction multiples. Materially different actual numbers may exist.

Open item: pull updated transaction data closer to actual Series A timing (modeled 2027 or later).

End of comp analysis. Regenerated 2026-07-22 against canon generation 8.